BAKGRUNN (fra kommisjonsforordningen)

(1) Commission Implementing Regulation (EU) No 686/2012 allocates the evaluation of the active substances deltamethrin, diflufenican, epoxiconazole, fluoxastrobin, prothioconazole and tebuconazole for the purposes of the renewal procedures to respective Member States, naming for each active substance a rapporteur and a co-rapporteur. 

(2) Commission Implementing Regulation (EU) No 2019/150 changes the allocation of the evaluation of those active substances to respectively other rapporteur Member States, following the notification submitted by the United Kingdom of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union. 

(3) The allocation is based on the consideration that the evaluation of the active substances concerned is at an advanced stage and the work to be carried out is expected to be minor. Therefore, no co-rapporteur Member State is allocated for that evaluation. 

(4) However, on 28 August 2023, the Authority requested pursuant to Article 13(3a) of Commission Implementing Regulation (EU) No 844/2012 additional information for the active substance deltamethrin, for the purposes of assessment of the approval criteria set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009. 

(5) Since Sweden is the evaluating competent authority for the renewal of the approval of the active substance deltamethrin in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council it is considered appropriate, with a view to facilitating coherence and efficiency in the evaluation under Regulation (EC) No 1107/2009 and Regulation (EU) No 528/2012, to allocate Sweden as a co-rapporteur Member State for the purposes of the renewal of the approval of deltamethrin. 

(6) Implementing Regulation (EU) No 686/2012 should therefore be amended accordingly. 

(7) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,